Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer’s Association International Conference (AAIC) Symposium Session

Posted by & filed under News.

Pittsburgh, July 23, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder and Chief Science Officer Susan Catalano, Ph.D. presented additional findings supporting the unique synaptorestorative mechanism of action of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, at the Alzheimer’s… Read more »

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease

Posted by & filed under News.

First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration… Read more »

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

Posted by & filed under News.

PITTSBURGH, May 22, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6.6 million…. Read more »

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Posted by & filed under News.

Pittsburgh, March 14, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the company’s co-founder and chief science officer, Dr. Susan Catalano, is presenting Phase 1b/2a results demonstrating the unique synaptoprotective mechanism of action… Read more »

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

Posted by & filed under News.

PITTSBURGH, Feb. 12, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will be hosting one-on-one meetings at the Leerink Partners 7th Annual Global Healthcare Conference at the… Read more »

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Posted by & filed under News.

Pittsburgh, Jan. 04, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make two presentations at the upcoming Sachs Associates Neuroscience Innovation Forum on… Read more »

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Posted by & filed under News.

Pittsburgh, Nov. 08, 2017 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at… Read more »

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

Posted by & filed under News.

PITTSBURGH, Nov. 4, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today the presentation of the results of a randomized, multi-dose, placebo-controlled Phase 1b/2a clinical study (COG0102) of CT1812 as a Late-Breaking Oral Communication and… Read more »

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

Posted by & filed under News.

PITTSBURGH, Oct. 30, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the biomarker and clinical results from the recently completed Phase 1b/2a clinical study (COG0102) of CT1812 will be presented in a Late-Breaking Poster… Read more »

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Posted by & filed under News.

Pittsburgh, Oct. 24, 2017 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a composition of matter patent for CT1812, Cognition’s first-in-class, orally available… Read more »